Helix BioPharma Net Income Over Time
| HBP Stock | CAD 1.84 0.01 0.54% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Helix BioPharma Performance and Helix BioPharma Correlation. Helix |
Cross Equities Net Income Analysis
Compare Helix BioPharma Corp and related stocks such as Satellos Bioscience, Cannara Biotech, and HLS Therapeutics Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LOVE | (2.1 M) | (2.1 M) | (2.1 M) | (2.1 M) | (2.1 M) | (2.1 M) | (2.1 M) | (2.1 M) | (12.3 M) | (12.5 M) | (1.5 M) | 2.3 M | 6.9 M | 6.4 M | 13.1 M | 15 M | 15.8 M |
| HLS | 6.9 M | 12 M | 16.9 M | 9.7 M | 12.7 M | (1.7 M) | (874.9 K) | (6.1 M) | (24.8 M) | (19.6 M) | (15.3 M) | (13.1 M) | (23.6 M) | (27.5 M) | (19.7 M) | (17.7 M) | (16.8 M) |
| MDNA | (765.8 K) | (765.8 K) | (765.8 K) | (765.8 K) | (833.5 K) | (1.3 M) | (7.6 M) | (7.5 M) | (4.7 M) | (8.3 M) | (17.2 M) | (22.6 M) | 1.5 M | (25.5 M) | (11.8 M) | (10.6 M) | (11.2 M) |
| CRDL | (1.7 M) | (1.7 M) | (1.7 M) | (1.7 M) | (1.7 M) | (1.7 M) | (1.7 M) | (1.7 M) | (15.9 M) | (14 M) | (20.6 M) | (24.7 M) | (11.5 M) | (28.1 M) | (36.7 M) | (33 M) | (31.4 M) |
| QIPT | (34.1 K) | (548 K) | (2.5 M) | (1.4 M) | (18.3 M) | (57.4 M) | (19.2 M) | 14.5 M | (5.6 M) | (4.6 M) | (6.2 M) | 4.8 M | (2.8 M) | (6.8 M) | (10.7 M) | (9.6 M) | (9.1 M) |
| SVA | (21.7 K) | (2.6 M) | (2 M) | (2.7 M) | (2.9 M) | (2.5 M) | (2.6 M) | (3.7 M) | (4 M) | (5.4 M) | (7 M) | (24.5 M) | (39 M) | (32.2 M) | (15.7 M) | (14.2 M) | (13.5 M) |
| RVX | (39.2 K) | (18.8 M) | 43.4 M | (55.1 M) | 18.3 M | (19.7 M) | (46.2 M) | (58.3 M) | (162.8 K) | 118 M | 2.5 K | (24.8 M) | (3.6 M) | (16.7 M) | (7.6 M) | (8.8 M) | (9.2 M) |
Helix BioPharma Corp and related stocks such as Satellos Bioscience, Cannara Biotech, and HLS Therapeutics Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Helix BioPharma Corp financial statement analysis. It represents the amount of money remaining after all of Helix BioPharma Corp operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| Helix BioPharma Corp | HBP |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 1055 West Georgia |
| Exchange | Toronto Exchange |
CAD 1.84
Other Information on Investing in Helix Stock
Helix BioPharma financial ratios help investors to determine whether Helix Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Helix with respect to the benefits of owning Helix BioPharma security.